A new study found that measuring circulating tumor cells (CTCs), rare cancer cells shed from tumors into the blood, is a reliable way to predict later treatment response and survival prospects.
Advertisement CTCs are rare cancer cells that tumors shed in the blood. They've been looked at before in prostate cancer, but only in its later stages. "No one, until now, has looked at whether ...
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter and nine months ended September 30, 2024. Third ...
This initiative is expected to impart higher revenues to Acadia Healthcare from its Comprehensive Treatment Centers (CTCs) and subsequently, contribute to the overall top line of the behavioral ...
The ONCObind Procedure Hemoperfusion Filter is the product brand name for the Onco-Seraph platform technology, an extracorporeal blood filtration procedure designed to target and filter out CTCs ...